


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">31199705</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1744-5116</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>57</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmaceutical biology</Title>
                <ISOAbbreviation>Pharm Biol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of huoxin formula on the arterial functions of patients with coronary heart disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>13-20</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1080/13880209.2018.1561726</ELocationID>
            <Abstract>
                <AbstractText><b>Context:</b> Huoxin formula is a Traditional Chinese Medicine for coronary heart disease (CHD) treatment. <b>Objective:</b> To explore the therapeutic mechanism of the Huoxin formula on arterial functions in CHD patients. <b>Materials and methods:</b> Fifty-eight CHD patients receiving cardiovascular drugs including β-receptor blocker, statins, and antiplatelet medications or others were randomized into intervention [additionally 13.5 g Huoxin formula granules dissolved in 150 mL warm water per time, twice a day (<i>n</i> = 30)] and control [only cardiovascular drugs (<i>n</i> = 28)] groups. Serum biomarkers (hs-CRP, IL-18, IL-17, TNF-α, MMP-9), and cardiovascular indicators of the common and internal carotid arteries (ICAs) were monitored before and after the treatments. <b>Results:</b> After 3 months of treatment, the increases of intima-media thicknesses (IMT) of the left and right common carotid arteries (CCAs) as well as of the left and right ICAs and the increases of the left and right cardio-ankle vascular index were all significantly (all <i>p</i> &lt; 0.001) less in the intervention than in control group (all <i>p</i> &lt; 0.001). Serum concentrations reductions of hs-CRP, IL-18, IL-17 and MMP9 (all <i>p</i> &lt; 0.001) levels were higher in the intervention compared to the control group, which correlated with the changes of left ICA (hs-CRP: <i>r</i> = 0.581, <i>p</i> = 0.009; IL-18: <i>r</i> = 0.594, <i>p</i> = 0.007; IL-17: <i>r</i> = 0.575, <i>p =</i> 0.006). <b>Discussion and conclusion:</b> Since the Huoxin formula improved arterial functions and reduced inflammatory factor activities in CHD patients, a large-scale clinical trial is warranted.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Department of Cardiology , Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine , Shanghai , China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Hongyi</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>b Department of Gastroenterology , Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine , Shanghai , China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Yi</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>c Department of Nephropathy , Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine , Shanghai , China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cen</LastName>
                    <ForeName>Rong</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>d Endoscopic Department , Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine , Shanghai , China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yao</LastName>
                    <ForeName>Chengzeng</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Department of Cardiology , Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine , Shanghai , China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Wenhuan</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>e Department of Cardiology , Zhabei District TCM Hospital , Shanghai , China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Minhua</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>f Department of Cardiology , Shanghai BaoShan District Combine Traditional Chinese and Western Medicine Hospital , Shanghai , China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yin</LastName>
                    <ForeName>Yahui</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Department of Cardiology , Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine , Shanghai , China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Hongzhi</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Department of Cardiology , Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine , Shanghai , China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Yongming</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Department of Cardiology , Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine , Shanghai , China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Endler</LastName>
                    <ForeName>Alexander</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>g Department of Molecular Medical Research , Tokyo Metropolitan Institute of Medical Science , Tokyo , Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Pharm Biol</MedlineTA>
            <NlmUniqueID>9812552</NlmUniqueID>
            <ISSNLinking>1388-0209</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ABI</Keyword>
            <Keyword MajorTopicYN="N">CAVI</Keyword>
            <Keyword MajorTopicYN="N">IMT</Keyword>
            <Keyword MajorTopicYN="N">hsCRP</Keyword>
            <Keyword MajorTopicYN="N">inflammatory factor</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31199705</ArticleId>
            <ArticleId IdType="doi">10.1080/13880209.2018.1561726</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

